PrEP

Three HIV screening strategies identified comparable numbers of new HIV diagnoses, a new study found.

Patients given a 600 mg injection of cabotegravir still had detectable levels of the drug in plasma, tissues, and fluids for 12 weeks.

A recent study of sexually active young women in Africa found that initiation of HIV preexposure prophylaxis (PrEP) was high at 95% and one-fifth showed high adherence at 6 months.

The risk of COVID-19 severity in people living with HIV may be less than previously anticipated.

Phase 3 trials for islatravir are underway. What are investigators considering with the Merck investigative drug?

Due to limited familiarity with providing antiretroviral medication, many participants were hesitant to initiate PrEP.

Investigators wanted to study usage of F/TAF vs F/TDF in clinical practice and HIV seroconversion.

Adherence for daily dosing decreased and event-driven PrEP usage increased in a Chinese study.

In a pilot project, customers were surveyed about HIV risk behaviors to gain further insights and assessed for potential PrEP utilization.

New 24-week findings from Merck highlight the potential of a 1-month PrEP option for low-risk patients.

Many respondents reported having a lack of information about the use of PrEP.

More tailored strategies could improve PrEP provision in family planning clinics.

A meta-analysis study found that 70% of PrEP users either stopped or had inadequate adherence within 6 months of initiation.

Small survey from gay and bisexual men (GBM) inquired about their experiences during COVID-19 restrictions, and feedback on PrEP.

In Brazil, a concerted effort of recruiting adolescents was made to go out and talk with them about PrEP.

Rates of testing for HIV, as well as PrEP uptake, remain suboptimal in MSM of color.

US residents with HIV have higher rates of mortality than their peers without infection, but the gap is narrowing, a recent study showed.

Investigators surveyed men who have sex with men (MSM) about long-acting injectable pre-exposure prophylaxis (PrEP) including attitudes towards potentially taking it and barriers to usage.

The pandemic's effect on in-person care prioritization may have indirectly influenced the rate of screening opportunities in at-risk persons.

Perspective gained from persons treated a real-world clinic may help better inform strategies to treat an HIV population that often struggles with viral suppression and consistent care.

A new study from IAS 2021 suggests persons with HIV hospitalized for COVID-19 do not face worse mortality nor major cardiovascular event risk.

Results from the study highlight the importance of PrEP education in clinical settings.

As younger generations come of age, there is a continuous need to inform them about HIV risks, offer insights about prevention strategies, and understand the challenges for people living with HIV (PLWH).

PrEP use is estimated to prevent >90% of infections in men who have sex with men and 70% of infections in people who inject drugs.

A new Australian study shows the infection rate was 1.61 cases per 1000 people per year over a 3 year study period in participants with access to the therapy.

More treatment options and modalities are now available for patients.

This is our inaugural segment for our new video series, 1 Big Question, where we ask the medical community a question about a significant infectious disease topic and get feedback from them.

Dapivrine (DPV) was studied in 1-month and 3-month durations.

Rising costs from 2014-2018 may have hindered PrEP expansion, according to a recent retrospective study.

Why it's critical for the future of HIV prevention for programs like the California PrEP-AP to reach younger at-risk persons now.